United Therapeutics Corporation (UTHR)
NASDAQ: UTHR · Real-Time Price · USD
471.92
+5.52 (1.18%)
At close: Nov 17, 2025, 4:00 PM EST
475.00
+3.08 (0.65%)
After-hours: Nov 17, 2025, 4:30 PM EST
United Therapeutics Revenue
United Therapeutics had revenue of $799.50M in the quarter ending September 30, 2025, with 6.76% growth. This brings the company's revenue in the last twelve months to $3.13B, up 13.50% year-over-year. In the year 2024, United Therapeutics had annual revenue of $2.88B with 23.63% growth.
Revenue (ttm)
$3.13B
Revenue Growth
+13.50%
P/S Ratio
6.66
Revenue / Employee
$2,397,241
Employees
1,305
Market Cap
20.32B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 2.88B | 549.90M | 23.63% |
| Dec 31, 2023 | 2.33B | 391.20M | 20.20% |
| Dec 31, 2022 | 1.94B | 250.80M | 14.88% |
| Dec 31, 2021 | 1.69B | 202.20M | 13.63% |
| Dec 31, 2020 | 1.48B | 34.50M | 2.38% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 58.13B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.58B |
UTHR News
- 7 days ago - United Therapeutics Corporation (UTHR) Presents at UBS Global Healthcare Conference 2025 Transcript - Seeking Alpha
- 13 days ago - United Therapeutics Corporation to Present at Upcoming Investor Conferences - Business Wire
- 14 days ago - United Therapeutics Corporation Announces First Transplant in EXPAND Clinical Trial of UKidney in Patients With End-Stage Renal Disease - Business Wire
- 19 days ago - United Therapeutics Corporation (UTHR) Q3 2025 Earnings Call Transcript - Seeking Alpha
- 19 days ago - United Therapeutics Corporation Reports Record Third Quarter 2025 Financial Results - Business Wire
- 4 weeks ago - United Therapeutics Corporation to Report Third Quarter 2025 Financial Results Before Market Open on Wednesday, October 29, 2025 - Business Wire
- 5 weeks ago - United Therapeutics to Feature Clinical Data at the CHEST 2025 Annual Meeting - Business Wire
- 7 weeks ago - United Therapeutics Corporation - Special Call - Seeking Alpha